Sec Form 4/A Filing - CR Group L.P. @ T2 Biosystems, Inc. - 2023-07-03

FORM 4/A Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person CR Group L.P. 2. Issuer Name and Ticker or Trading Symbol T2 Biosystems, Inc. [ TTOO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 1000 MAIN STREET, SUITE 2500 3. Date of Earliest Transaction (MM/DD/YY) 07/03/2023 (Street) HOUSTON, TX77002 4. If Amendment, Date Original Filed (MM/DD/YY) 07/06/2023 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series B Convertible Preferred Stock ( 1 ) $ 0.0706 07/03/2023 A 33,595 ( 2 ) ( 2 ) Common Stock 33,595,000 ( 2 ) ( 3 ) 33,595 I By CRG Partners III (Cayman) Lev AIV I L.P. Series B Convertible Preferred Stock ( 1 ) $ 0.0706 07/03/2023 A 59,703 ( 2 ) ( 2 ) Common Stock 59,703,000 ( 2 ) ( 3 ) 59,703 I By CRG Partners III Parallel Fund (B) (Cayman) L.P.

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other CR Group L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77002 X CRG Partners III L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77002 X CRG Partners III - Parallel Fund (A) L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77002 X CRG Partners III (Cayman) Unlev AIV I L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77002 X CRG Partners III (Cayman) Lev AIV I L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77002 X CRG Partners III - Parallel Fund B (Cayman) L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77002 X Signatures /s/ Nathan D. Hukill, authorized signatory for CRG Partners III L.P., CRG Partners III Parallel Fund (A) L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund (B)(Cayman) L.P. 07/14/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The acquisition of these shares was inadvertently omitted from the reporting persons' Form 4 filed with the SEC on July 6, 2023. ( 2 )Each share of Series B Convertible Preferred Stock (the "Series B Preferred") converts into 1,000 shares of the Company's common stock at the holder's election, subject to beneficial ownership limitations, including that a holder of Series B Preferred is prohibited from converting such shares into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. As a result of the 19.99% beneficial ownership limitation, as of July 3, 2023, the Series B Preferred held by the reporting persons can be converted into a maximum of 24,157,794 shares of common stock in the aggregate. The shares of Series B Preferred have no expiration date. ( 3 )Pursuant to that certain Securities Purchase Agreement, dated July 3, 2023, by and among the Company, CRG Partners III L.P., CRG Partners III - Parallel Fund "A" L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund "B" (Cayman) L.P. (collectively, the "CRG Entities"), the CRG Entities received these shares in exchange for the CRG Entities surrendering for cancellation of certain outstanding debt.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.